Preimplantation genetic diagnosis: an update on current technologies and ethical considerations
Preimplantation genetic diagnosis: an update on current technologies and ethical considerations
复制标题
DOI：
10.1007/s12522-015-0224-6
复制
发表时间：
2016-04-01
影响因子：
3.4
通讯作者：
Sueoka, Kou
中科院分区：
文献类型：
--
作者：
Sueoka, Kou
生殖医学的目的是支持健康儿童的出生。辅助生殖技术和遗传分析的进步导致胚胎植入前遗传学诊断（PGD）的引入。PGD的适应症一直是伦理和法律领域的一个主要话题。不同国家、宗教、人口和社会阶层的担忧各不相同，新技术的持续快速发展也不尽相同。与道德的增强相反，技术以过快的速度发展。最近最重要的技术发展提供了通过微阵列或下一代测序方法对单个胚胎细胞进行全基因组扩增和测序的能力。随着新的负担得起的技术被引入，患者面临着越来越多的PGD选择。同时，遗传信息检测和处理指征的伦理准则也必须迅速适应这些变化。
The aim of reproductive medicine is to support the birth of healthy children. Advances in assisted reproductive technologies and genetic analysis have led to the introduction of preimplantation genetic diagnosis (PGD) for embryos. Indications for PGD have been a major topic in the fields of ethics and law. Concerns vary by nation, religion, population, and segment, and the continued rapid development of new technologies. In contrast to the ethical augment, technology has been developing at an excessively rapid speed. The most significant recent technological development provides the ability to perform whole genome amplification and sequencing of single embryonic cells by microarray or next-generation sequencing methods. As new affordable technologies are introduced, patients are presented with a growing variety of PGD options. Simultaneously, the ethical guidelines for the indications for testing and handling of genetic information must also rapidly correspond to the changes.